DATA GRAPHICS | Data Byte
EMA’s CHMP backs new medicines from Hansoh, Cytokinetics
Five new drugs and vaccines recommended at committee’s December meeting
December 12, 2025 10:32 PM UTC
Hansoh is poised for its first EU product approval after CHMP recommended authorizing Aumseqa aumolertinib to treat non-small cell lung cancer with specific mutations. The EGFR tyrosine kinase inhibitor is already approved in China and the U.K.; in June, the company said it was the first Chinese EGFR TKI to be launched overseas.
Hansoh Pharmaceutical Group Co. Ltd. (HKEX:03692) originally licensed aumolertinib’s ex-China rights to EQRx Inc., which terminated the deal concurrently with its acquisition by Revolution Medicines Inc. (NASDAQ:RVMD)...